24/7 Market News Snapshot 05 June, 2025 – Immunic, Inc. Common Stock (NASDAQ:IMUX)

June 5, 2025

DENVER, Colo., 05 June, 2025 (www.247marketnews.com) – (NASDAQ:IMUX) are discussed in this article.
Immunic, Inc. (IMUX) has recently marked a significant bullish trend, with shares trading at $1.008—a remarkable 30.06% increase from the previous close of $0.775 during pre-market sessions. This surge, driven by a trading volume of 4.71 million shares, reflects a strong surge in investor interest and confidence in the company’s potential for substantial growth. Technical indicators suggest that the stock is well-positioned for further upside as it breaks through critical resistance levels, encouraging market participants to monitor this dynamic stock closely for opportunities.

Amidst this optimistic market activity, Immunic has also announced the successful completion of enrollment in both Phase 3 ENSURE trials concerning vidofludimus calcium, a promising new therapy targeting relapsing multiple sclerosis (RMS). This achievement adds to the enthusiasm surrounding Immunic’s mission to innovate treatment options for chronic inflammatory and autoimmune diseases. The ENSURE program includes two multicenter, randomized, double-blind trials, ENSURE-1 and ENSURE-2, engaging over 2,200 adult RMS patients, designed to evaluate the therapy’s safety and efficacy compared to placebo, focusing primarily on the time to first relapse over a 72-week period.

Dr. Daniel Vitt, CEO of Immunic, expressed satisfaction with the enrollment completion, highlighting it as a reflection of the team’s dedication. He emphasized the evaluation of vidofludimus calcium’s unique neuroprotective properties and indicated that top-line data from both trials is anticipated by the end of 2026. Furthermore, emerging data from the Phase 2 CALLIPER trial corroborates the neuroprotective potential of vidofludimus calcium, noting reductions in disability worsening among progressive MS patients.

As Immunic advances its regulatory submissions and prepares for the potential commercialization of vidofludimus calcium, the company remains committed to improving patient outcomes and revolutionizing oral therapies for multiple sclerosis, marking an important step in addressing chronic disease management.

Related news for (IMUX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.